Endometrial Neoplasms

• EMA approval · 2026-07-01
  EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.

  EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…

• EMA approval · 2026-06-10
  EMA Authorised: Jemperli (dostarlimab) — GlaxoSmithKline Trading Services Limited

  EMA has authorised Jemperli (dostarlimab) for endometrial neoplasms, expanding therapeutic options in this area.